IL315254A - Human 3E10 antibodies, variants and antigen-binding fragments thereof - Google Patents

Human 3E10 antibodies, variants and antigen-binding fragments thereof

Info

Publication number
IL315254A
IL315254A IL315254A IL31525424A IL315254A IL 315254 A IL315254 A IL 315254A IL 315254 A IL315254 A IL 315254A IL 31525424 A IL31525424 A IL 31525424A IL 315254 A IL315254 A IL 315254A
Authority
IL
Israel
Prior art keywords
humanized
antibodies
variants
antigen binding
binding fragments
Prior art date
Application number
IL315254A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Yale
Gennao Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Gennao Bio Inc filed Critical Univ Yale
Publication of IL315254A publication Critical patent/IL315254A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL315254A 2022-03-03 2023-03-02 Human 3E10 antibodies, variants and antigen-binding fragments thereof IL315254A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263316338P 2022-03-03 2022-03-03
PCT/US2023/063605 WO2023168352A1 (en) 2022-03-03 2023-03-02 Humanized 3e10 antibodies, variants, and antigen binding fragments thereof

Publications (1)

Publication Number Publication Date
IL315254A true IL315254A (en) 2024-10-01

Family

ID=85772764

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315254A IL315254A (en) 2022-03-03 2023-03-02 Human 3E10 antibodies, variants and antigen-binding fragments thereof

Country Status (12)

Country Link
US (1) US20230303719A1 (enExample)
EP (1) EP4486459A1 (enExample)
JP (1) JP2025507840A (enExample)
KR (1) KR20240168484A (enExample)
CN (1) CN119421901A (enExample)
AR (1) AR128689A1 (enExample)
AU (1) AU2023228912A1 (enExample)
CA (1) CA3254017A1 (enExample)
IL (1) IL315254A (enExample)
MX (1) MX2024010593A (enExample)
TW (1) TW202346364A (enExample)
WO (1) WO2023168352A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021042060A1 (en) 2019-08-30 2021-03-04 Yale University Compositions and methods for delivery of nucleic acids to cells
WO2023168427A1 (en) * 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
EP4642488A1 (en) 2022-12-27 2025-11-05 Yale University Antibody drug conjugates
WO2024158824A1 (en) 2023-01-23 2024-08-02 Yale University Antibody oligonucleotide conjugates
EP4683674A1 (en) 2023-03-23 2026-01-28 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping
WO2025097000A1 (en) 2023-11-01 2025-05-08 Yale University Antibody-based methods for treating polycystic kidney disease
CN117924517A (zh) * 2024-01-02 2024-04-26 河北神宇生物技术有限公司 一种靶向穿膜重组蛋白及其应用
WO2025213130A1 (en) * 2024-04-04 2025-10-09 Yale University Antibody drug conjugates
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812397A (en) 1987-02-10 1989-03-14 The Regents Of The University Of California MAB-anti-DNA related to nephritis
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
AU707440B2 (en) 1994-03-29 1999-07-08 Celltech Therapeutics Limited Antibodies against E-selectin
JP2000507225A (ja) 1996-03-08 2000-06-13 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア ｍａｂ ３Ｅ１０ ならびにその突然変異体および／または機能性フラグメントを使用する送達システム
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
JP2007501021A (ja) 2003-05-30 2007-01-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 遺伝子操作された定常領域を含む、抗体および融合タンパク質
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
ES2911034T3 (es) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
DK2176408T5 (en) 2008-01-31 2015-12-14 Curevac Gmbh Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS.
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
US20110184045A1 (en) 2008-06-30 2011-07-28 Gunther Hartmann Silencng and rig-i activation by dual function oligonucleotides
US8961967B2 (en) 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
JP5956982B2 (ja) 2010-05-27 2016-07-27 メルク・シャープ・エンド・ドーム・コーポレイション 改善された特性を有する抗体の製造方法
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
WO2013064584A1 (en) 2011-10-31 2013-05-10 Riboxx Gmbh Double-stranded RNA for immunostimulation
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
WO2014169049A1 (en) 2013-04-09 2014-10-16 Duke University 2' fluoro-modified rnas as immunostimulators
US9775894B2 (en) 2013-07-09 2017-10-03 University Of Washington Through Its Center For Commercialization Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
AU2015204446A1 (en) * 2014-01-13 2016-07-14 Valerion Therapeutics, Llc Internalizing moieties
WO2016033321A1 (en) 2014-08-28 2016-03-03 Yale University Multivalent fragments of antibody 3e10 and methods of use thereof
DE102015008536A1 (de) 2015-07-02 2017-01-05 Rheinische Friedrich-Wilhelms-Universität Bonn Diskontinuierliche Oligonukleotid-Liganden
WO2017079369A2 (en) 2015-11-03 2017-05-11 Glaxosmithkline Llc Novel antibodies
WO2017173427A1 (en) 2016-04-01 2017-10-05 Vycellix Inc Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
EP3471777A1 (en) 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
KR20190057083A (ko) 2016-10-06 2019-05-27 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 공정 불순물에 대한 결합이 감소된 항체
JP7062669B2 (ja) 2016-12-23 2022-05-06 ブリストル－マイヤーズ スクイブ カンパニー 改善されたバイオアナリシス特性およびバイオプロセシング特性のための、治療用免疫グロブリンｇ４の設計
US11382966B2 (en) 2017-03-24 2022-07-12 Rigontec Gmbh Method for designing RIG-I ligands
EP3655432A4 (en) * 2017-07-17 2021-04-14 Nucleus Therapeutics Pty Ltd BINDING PROTEINS 1
WO2019143297A1 (en) 2018-01-17 2019-07-25 Nanyang Technological University Immunomodulatory small hairpin rna molecules
US20210137960A1 (en) 2018-02-01 2021-05-13 Yale University Compositions and methods for inhibition of nuclear-penetrating antibodies
WO2019152806A1 (en) 2018-02-01 2019-08-08 Yale University Compositions and methods for enhancing nuclear translocation
WO2019152884A1 (en) 2018-02-02 2019-08-08 University Of Washington Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling
JP7366057B2 (ja) 2018-04-19 2023-10-20 チェックメイト ファーマシューティカルズ， インコーポレイテッド 合成ｒｉｇ－ｉ様受容体アゴニスト
EP3781687A4 (en) 2018-04-20 2022-02-09 Merck Sharp & Dohme Corp. NEW RIG-I SUBSTITUTED AGONISTS: COMPOSITIONS AND METHODS THEREOF
EP3810151B1 (en) 2018-06-20 2025-08-06 Yale University Rig-i agonists and treatments using same
CA3111186A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods for enhancing triplex and nuclease-based gene editing
EP3844287B1 (en) 2018-08-31 2024-05-22 Yale University Compositions and methods for enhancing donor oligonucleotide-based gene editing
EP3990635A1 (en) 2019-06-27 2022-05-04 Rigontec GmbH Design method for optimized rig-i ligands
EP4045656A1 (en) 2019-10-16 2022-08-24 SomaLogic Operating Co., Inc. Nucleic acid compounds that bind to retinoic acid-inducible gene i protein
AU2022302143A1 (en) 2021-07-02 2024-01-18 Yale University Compositions and methods for treating cancers

Also Published As

Publication number Publication date
KR20240168484A (ko) 2024-11-29
AR128689A1 (es) 2024-06-05
TW202346364A (zh) 2023-12-01
US20230303719A1 (en) 2023-09-28
WO2023168352A1 (en) 2023-09-07
EP4486459A1 (en) 2025-01-08
CN119421901A (zh) 2025-02-11
JP2025507840A (ja) 2025-03-21
CA3254017A1 (en) 2023-09-07
AU2023228912A1 (en) 2024-09-19
MX2024010593A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
IL315254A (en) Human 3E10 antibodies, variants and antigen-binding fragments thereof
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
HUE061425T2 (hu) Anti SARS-COV-2-tüske glikoprotein antitestek és antigénkötõ fragmentumok
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
EP1478764A4 (en) HUMANIZED COLLAGEN ANTIBODIES AND RELATED METHODS
WO2004001381A8 (en) Novel raag10 cell surface target and a family of antibodies recognizing that target
EP2684889A3 (en) Multivariable antigens complexed with targeting humanized monoclonal antibody
IL176940A (en) An isolated antibody or antigen-binding fragment thereof
IL291082A (en) Anti-vsig4 antibody or antigen-binding fragment and uses thereof
WO2006084264A3 (en) Cd20 antibody variants and uses thereof
EP4428151A4 (en) MONOCLONAL ANTI-TSLP ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND USE THEREOF
IL310012A (en) Antibodies against SARS-COV-2 spike glycoprotein and antigen-binding fragments
HRP20260098T1 (hr) Anti-gprc5d monoklonska protutijela i njihova upotreba
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
EP4043482A4 (en) TUMOR TARGETING PROTEIN OR ASSOCIATED FRAGMENT, ANTIBODIES BINDING THEREWITH AND ITS USE
IL319054A (en) Antibodies and antibody fragments to auristatin monomethyl
WO2021254574A3 (en) Cd38 antibodies for the treatment of human diseases
IL317849A (en) Anti-SLC34A2 monoclonal antibodies and their uses
IL325463A (en) Antigen-binding proteins against mageb2
WO2023129870A3 (en) ANTIBODIES SPECIFICALLY RECOGNIZING C5aR1 AND USES THEREOF
MX2022003191A (es) Terapias de combinacion con anticuerpos entpd2 y cd73.
IL317443A (en) Humanized antibodies or active parts thereof against cancer antigens
WO2024118931A3 (en) Anti-her2/trop2 antibodies and uses thereof
CA3308406A1 (en) Vasoinhibin binding monoclonal antibody or vasoinhibin binding fragment thereof
AU2022337266A1 (en) Monospecific and bispecific antibodies and antigen binding fragments thereof